Table 2. Broad-spectrum anti-HIV-1 (EC50) activity of LabyA1 against various HIV-1 clinical isolates representing different subtypes evaluated in PBMCs.
| Group | HIV-1 (coreceptor use) | Subtype | EC50 (µM)a |
| M | UG273 (clinical isolate; R5) | A | 1.9±0.1 |
| US2 (clinical isolate; R5/X4) | B | 0.70±0.19 | |
| CI#17 (clinical isolate; X4) | B | 1.0±0.2 | |
| DJ259 (clinical isolate; R5) | C | 0.94±0.43 | |
| ETH2220 (clinical isolate; R5) | C | 0.78±0.06 | |
| UG270 (clinical isolate; X4) | D | 1.5±0.1 | |
| NPO3 (clinical isolate; X4) | E | 1.6±0.3 | |
| ID12 (clinical isolate; R5) | A/E | 1.2±0.8 | |
| O | BCF-06 (clinical isolate; X4) | 0.83±0.33b | |
| Median EC50 | 1.0 µM | ||
a
EC50s measured by p24 Ag ELISA. Mean ± SEM out of 2–5 independent PBMC donor experiments is shown.
b
EC50 measured by p27 Ag ELISA. Mean ± SEM out of 4 independent PBMC donor experiments is shown.